Lupin unveils Paliperidone ER Tablets in US
Schizophrenia is frequently associated with significant distress and impairment in personal, family, social, educational, occupational, and other important areas of life.
Mumbai: Global pharma major Lupin Limited has announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg in the United States.
The product is a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development, LLC. The medicine is indicated for the treatment of Schizophrenia.
Schizophrenia is frequently associated with significant distress and impairment in personal, family, social, educational, occupational, and other important areas of life.
Read also: Lupin to acquire two inhalation medicines from Sunovion Pharma for over Rs 623 crore
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas.
Read also: Lupin Gets CDSCO Panel nod To study LUBT017 Biosimilar to Eylea
